PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Man Cai, Zhang, Ling Yi, Han, Wei, Shao, Yuan, Chen, Mo, Ni, Rui, Wang, Gen Nian, Wei, Feng Xian, Zhang, Ya Wu, Xu, Xiao Dong, Zhang, You Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603082/
https://www.ncbi.nlm.nih.gov/pubmed/25526490
http://dx.doi.org/10.1097/MD.0000000000000326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603082/
https://www.ncbi.nlm.nih.gov/pubmed/25526490
http://dx.doi.org/10.1097/MD.0000000000000326

Ejemplares similares